Results 11 to 20 of about 5,710 (181)

Evolocumab Reduces Oxidative Stress and Lipid Peroxidation in Obese Zucker Rats

Pathophysiology
Background/Objectives: Evolocumab inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to low-density lipoprotein (LDL) receptors, thus allowing more LDL receptors to remove LDL cholesterol from the blood.
Martina Cebova, Radoslava Bulkova, Olga Pechanova   +2 more
doaj   +2 more sources

Changing from lipoprotein apheresis to evolocumab treatment lowers circulating levels of arachidonic acid and oxylipins

Atherosclerosis Plus
Background and aims: Previous studies have shown that lipoprotein apheresis can modify the plasma lipidome and pro-inflammatory and pro-thrombotic lipid mediators.
Chaoxuan Wang, Anne Kaufmann, Nadja Kampschulte, Ulf Elbelt, Ursula Kassner, Elisabeth Steinhagen-Thiessen, Anne Pietzner, Christoph Schmöcker, Dev Datta, Tiziana Sanpietro, Nils Helge Schebb, Karsten-H. Weylandt, Nadine Rohwer   +12 more
doaj   +2 more sources

Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction

Vascular Health and Risk Management, 2016
Courtney A Henry, Ronald A Lyon, Hua Ling Department of Pharmacy Practice, School of Pharmacy, Hampton University, Hampton, VA, USA Abstract: Multiple categories of medications have been developed to manage lipid profiles and reduce the risk of ...
Henry CA, Lyon RA, Ling H
doaj   +1 more source

Evolocumab early reduces IL-1β/IL-17A and improves left ventricular function in STEMI: an observational study in the real world [PDF]

Frontiers in Pharmacology
BackgroundWhile proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) effectively lower low-density lipoprotein cholesterol (LDL-C) levels and reduce the incidence of major adverse cardiovascular events (MACE) in patients with ST-segment ...
Menglong Zhang, Jingyu Liu, Jingxian Wang, Anran Jing, Junfeng Zhang, Changping Li, Zhuang Cui, Yin Liu, Jing Gao, Jing Gao, Jing Gao   +10 more
doaj   +2 more sources

Clinical effect of proprotein convertase subtilisin/kexin type 9 inhibition in patients undergoing coronary artery bypass surgeryCentral MessagePerspective [PDF]

JTCVS Open
Objectives: To evaluate whether adding evolocumab to statin plus ezetimibe in patients undergoing coronary artery bypass grafting improves lipid control and reduces clinical events.
Giuseppe Nasso, MD, PhD, Alfredo Marchese, PhD, Giuseppe Santarpino, PhD, Walter Vignaroli, MD, Vincenzo Calabrese, MD, Giovanni Taverna, MD, Claudio Larosa, MD, Francesco Bartolomucci, MD, Flavio Fiore, MD, Mario Siro Brigiani, MD, Gaetano Contegiacomo, MD, Ernesto Greco, PhD, Giuseppe Speziale, PhD   +12 more
doaj   +2 more sources

Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study [PDF]

, 2022
INTRODUCTION The aims of this study were to describe patient characteristics, lipid parameters, lipid-lowering drug use, and safety of patients receiving evolocumab in a real-world clinical setting.
Rickli, Hans; https://orcid.org/, Carballo, David; https://orcid.org/, Reichert, Nina; https://orcid.org/, Mueller, Christian; https://orcid.org/, Sudano, Isabella; https://orcid.org/, Rossi, Mariagrazia; https://orcid.org/, Koskinas, Konstantinos C, Nanchen, David; https://orcid.org/, Bilz, Stefan; https://orcid.org/, Crljenica, Carmela; https://orcid.org/, Mach, François; https://orcid.org/   +10 more
core   +2 more sources

Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.

PLoS ONE, 2023
ObjectivesDyslipidemia is a prevalent condition with significant morbidity and mortality across the world, including in the Arabian Gulf. The present study aimed to describe the characteristics of patients receiving evolocumab in clinical practice ...
Khalid Al Faraidy, Mousa Akbar, Mohamed Shehri, Mohammad Aljarallah, Gamal Abdin Hussein, Raja Dashti, Ahmad Al Qudaimi, Fahad Al Nouri, Zuhier Awan, Ahmed Essam, Alaa Emara   +10 more
doaj   +1 more source

Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction [PDF]

, 2022
OBJECTIVES The purpose of this study was to determine the effect of evolocumab on optical coherence tomography (OCT) measures of plaque composition.
Prati, Francesco, Rishi Puri, Huei Wang, Daniel Aradi, Jones, Stephen, Nissen, Steven E, Thomas Hucko, Hucko, Thomas, Kataoka, Yu, Wang, Bei, Giuseppe Di Giovanni, Puri, Rishi, Stephen Jones, Psaltis, Peter J, Gianluca Pompili, Butters, Julie, Julie Butters, Francesco Prati, Yu Kataoka, Windecker, Stephan, Herrman, Jean-Paul R, Di Giovanni, Giuseppe, Renicus S. Hermanides, Bei Wang, Peter J. Psaltis, Wang, Huei, Hermanides, Renicus S, Aradi, Daniel, Stephen J. Nicholls, Stephan Windecker, Pompili, Gianluca, Jean-Paul R. Herrman, Steven E. Nissen, Nicholls, Stephen J   +33 more
core   +1 more source

Efficacy and Safety of Evolocumab in Chinese Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia: 12-Week Primary Results of the HUA TUO 华佗 Randomized Clinical Trial

Cardiology and Therapy, 2023
Introduction Evolocumab, a fully human proprotein convertase/subtilisin kexin type 9 inhibitor antibody, significantly lowers low-density lipoprotein cholesterol (LDL-C) in patients with type 2 diabetes mellitus and hyperlipidemia and mixed dyslipidemia.
Hong Tan, Weimin Li, Zhouqing Huang, Yajun Han, Xuecheng Huang, Dongye Li, Xiaochun Xing, Maria Laura Monsalvo, You Wu, Jackie Mao, Lily Xin, Jiyan Chen, HUA TUO study investigators   +12 more
doaj   +1 more source

Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study [PDF]

, 2020
Background: People living with human immunodeficiency virus (PLHIV) are at increased risk of atherosclerotic cardiovascular disease (ASCVD) and are prone to statin-related adverse events from drug-drug interactions with certain antiretroviral regimens ...
Kumar, Princy N, Rosenson, Robert S, Cyrille, Marcoli, Calmy, Alexandra, López, J Antonio G, Caramelli, Bruno, Bray, Sarah, BEIJERINCK Investigators, Boccara, Franck   +8 more
core   +2 more sources